1ONY

Oxalyl-Aryl-Amino Benzoic Acid inhibitors of PTP1B, compound 17


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.15 Å
  • R-Value Free: 0.220 
  • R-Value Work: 0.194 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Discovery and Structure-Activity Relationship of Oxalylarylaminobenzoic Acids as Inhibitors of Protein Tyrosine Phosphatase 1B

Liu, G.Szczepankiewicz, B.G.Pei, Z.Janowich, D.A.Xin, Z.Hadjuk, P.J.Abad-Zapatero, C.Liang, H.Hutchins, C.W.Fesik, S.W.Ballaron, S.J.Stashko, M.A.Lubben, T.Mika, A.K.Zinker, B.A.Trevillyan, J.M.Jirousek, M.R.

(2003) J.Med.Chem. 46: 2093-2103

  • DOI: 10.1021/jm0205696
  • Primary Citation of Related Structures:  1ONZ

  • PubMed Abstract: 
  • Protein Tyrosine phosphatase 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling pathways. Using an NMR-based screening approach with 15N- and 13C-labeled PTP1B, we have identified 2,3-dimethylphenyloxalyla ...

    Protein Tyrosine phosphatase 1B (PTP1B) has been implicated as a key negative regulator of both insulin and leptin signaling pathways. Using an NMR-based screening approach with 15N- and 13C-labeled PTP1B, we have identified 2,3-dimethylphenyloxalylaminobenzoic acid (1) as a general, reversible, and competitive PTPase inhibitor. Structure-based approach guided by X-ray crystallography facilitated the development of 1 into a novel series of potent and selective PTP1B inhibitors occupying both the catalytic site and a portion of the noncatalytic, second phosphotyrosine binding site. Interestingly, oral biovailability has been observed in rats for some compounds. Furthermore, we demonstrated in vivo plasma glucose lowering effects with compound 12d in ob/ob mice.


    Related Citations: 
    • Potent, Selective Inhibitors of Protein Tyrosine Phosphatase 1B
      Xin, Z.,Oost, T.K.,Abad-Zapatero, C.,Hajduk, P.J.,Pei, Z.,Szczepankiewicz, B.G.,Hutchins, C.W.,Ballaron, S.J.,Stashko, M.A.,Lubben, T.,Trevillyan, J.M.,Jirousek, M.R.,Liu, G.
      (2003) BIOORG.MED.CHEM.LETT. 13: 1887
    • Potent, Selective Protein Tyrosine Phosphatase 1B Inhibitor Using a Linked-Fragment Strategy
      Szczepankiewicz, B.G.,Liu, G.,Hajduk, P.J.,Abad-Zapatero, C.,Pei, Z.,Xin, Z.,Lubben, T.,Trevillyan, J.M.,Stashko, M.A.,Ballaron, S.J.,Liang, H.,Huang, F.,Hutchins, C.W.,Fesik, S.W.,Jirousek, M.R.
      (2003) J.Am.Chem.Soc. 125: 4087


    Organizational Affiliation

    Metabolic Disease Research and Advanced Technology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064-6098, USA. gang.liu@abbott.com




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Protein-tyrosine phosphatase, non-receptor type 1
A
321Homo sapiensGene Names: PTPN1 (PTP1B)
EC: 3.1.3.48
Find proteins for P18031 (Homo sapiens)
Go to Gene View: PTPN1
Go to UniProtKB:  P18031
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
588
Query on 588

Download SDF File 
Download CCD File 
A
2-{[2-(2-CARBAMOYL-VINYL)-4-(2-METHANESULFONYLAMINO-2-PENTYLCARBAMOYL-ETHYL)-PHENYL]-OXALYL-AMINO}-BENZOIC ACID
COMPOUND 17
C27 H32 N4 O9 S
FSRCMOQVSVRBJH-RPAADVPWSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
588Ki: 170 - 251 nM (100) BINDINGDB
588Ki: 170 nM PDBBIND
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.15 Å
  • R-Value Free: 0.220 
  • R-Value Work: 0.194 
  • Space Group: P 31 2 1
Unit Cell:
Length (Å)Angle (°)
a = 89.015α = 90.00
b = 89.015β = 90.00
c = 105.352γ = 120.00
Software Package:
Software NamePurpose
MAR345data collection
CNXphasing
CNXrefinement
HKL-2000data scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2003-05-20
    Type: Initial release
  • Version 1.1: 2008-04-29
    Type: Version format compliance
  • Version 1.2: 2011-07-13
    Type: Version format compliance
  • Version 1.3: 2017-10-11
    Type: Refinement description